DIFFERENTIATION OF STEM CELLS FROM UMBILICAL CORD MATRIX INTO HEPATOCYTE LINEAGE CELLS
First Claim
Patent Images
1. A method for differentiating umbilical cord matrix cells into hepatocyte-like cells, comprising:
- a. contacting umbilical cord matrix cells with Pre-induction Media;
b. contacting umbilical cord matrix cells with Differentiation Media; and
c. contacting umbilical cord matrix cells with Maturation Media;
for a time sufficient to differentiate the umbilical cord matrix cells into hepatocyte-like cells.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to methods for differentiating umbilical cord matrix cells into hepatocyte-like cells and compositions and methods for using such hepatocyte-like cells.
14 Citations
26 Claims
-
1. A method for differentiating umbilical cord matrix cells into hepatocyte-like cells, comprising:
-
a. contacting umbilical cord matrix cells with Pre-induction Media;
b. contacting umbilical cord matrix cells with Differentiation Media; and
c. contacting umbilical cord matrix cells with Maturation Media;
for a time sufficient to differentiate the umbilical cord matrix cells into hepatocyte-like cells. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
- 17. A panel of umbilical cord matrix-derived hepatocyte-like cells comprising at least two umbilical cord matrix-derived hepatocyte-like cells wherein the at least two umbilical cord matrix-derived hepatocyte-like cells are derived from different subjects, and wherein the umbilical cord matrix-derived hepatocyte-like cells are separate one from the other.
-
26. A method for differentiating umbilical cord matrix cells into hepatocyte-like cells, comprising:
-
a. seeding umbilical cord matrix cells on a 0.1% gelatin coated tissue culture plate;
b. contacting umbilical cord matrix cells with a Pre-induction Media comprising 10-30 ng/ml recombinant human epidermal growth factor and 5-15 ng/ml recombinant human basic fibriblast growth factor;
c. contacting umbilical cord matrix cells with a Differentiation Media comprising 10-30 ng/ml recombinant human hepatocyte growth factor, 5-15 ng/ml rhbFGF and 0.5-1.0 g/L nicotinamide; and
d. contacting umbilical cord matrix cells with a Maturation Media comprising 10-30 ng/ml Human Oncostatin M, 0.5-1.5 umol/L dexamethasone and 30-70 mg/ml ITS+ premix;
for a time sufficient to differentiate the umbilical cord matrix cells into hepatocyte-like cells.
-
Specification